The future of gene patents and the implications for medicine

JAMA Internal Medicine

Volumn 173, Issue 17, 2013, Pages 1569-1570

  Sherkow, Jacob S ^a   Greely, Henry T ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; MESSENGER RNA;

BIOTECHNOLOGY; BRCA2 GENE; BREAST CANCER; CANCER RISK; DNA SEQUENCE; GENE; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; MEDICINE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PATENT; PRIORITY JOURNAL; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BRCA2 PROTEIN; COMMERCE; ECONOMIC COMPETITION; FORECASTING; GENES; HUMANS; INDIVIDUALIZED MEDICINE; PATENTS AS TOPIC; PATHOLOGY, MOLECULAR; SUPREME COURT DECISIONS; UNITED STATES;

EID: 84884698594     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.10153     Document Type: Short Survey

References (7)

1. Association for Molecular Pathology v Myriad Genetics Inc, 12-398 US (2013). http://www.supremecourt.gov/opinions/12pdf/12-398 -1b7d.pdf. Accessed June 25, 2013.
2. Banks G. Justices reject patent on gene. Pittsburgh Post-Gazette. June 14, 2013, §A1.
3. Biotechnology Industry Organization. Statement on US Supreme Court review of isolated DNA patents. http://www.bio.org/media/press-release/statement-us- supreme-court-review-isolated-dna -patents. Accessed June 25, 2013.
4. 35 USC § 101, Inventions patentable.
5. Diamond v Chakrabarty, 447 US 303 (1980).
6. Parke-Davis & Co. v H. K. Mulford Co, 189 F 95 (CCSDNY 1911).
7. Merrill SA, Mazza AM; National Research Council (US) Committee on Intellectual Property Rights in Genomic and Protein Research and Innovation. Reaping the benefits of genomic and proteomic research: intellectual property rights, innovation, and public health. http://www.ncbi.nlm.nih.gov/books/ NBK19865/. Accessed June 25, 2013.